Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
MarketBeat

PolyPid Q1 Earnings Call Highlights

PolyPid (NASDAQ:PYPD) said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate for preventing surgical site infections in abdominal colorectal surgery.

Chief Executive Officer Dikla Czaczkes Akselbrad told investors that the company’s priorities are advancing D-PLEX100 toward potential U.S. Food and Drug Administration approval and finalizing a U.S. strategic partnership intended to support a commercial launch in the first quarter of 2027.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.